The company remains cautious on full-fledged recovery, given concerns over a second wave of Covid-19
Revenue growth, however, could stabilise once recovery picks up
While deal pipeline remains strong, Q3 growth, valuations could impact stock
Gains in domestic revenues and margin in Q2 offset weak global business
ARPU expansion, market share gains expected even if there is no tariff hike
The company, which has received the go ahead on merger with Indus Towers, expects the trend to continue in the near term
Wipro was lagging its peers in the past on the back of muted revenue growth, falling margins, loss of market share in deal renewals and pricing pressures
Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches
Brokerages expect mobile volumes to rise multi-fold over the next two years
While the September quarter could be another washout, there are some positive triggers which could lead to demand improvement
Some of the gains could be offset by weak India business and the oil and gas vertical
Exim rail volumes at 4.3 million tonnes have hit their highest levels since August last year
Margins would, however, continue to be muted on lower studded ornament sales and discounts
Domestic volume trajectory and rising cash flows are the other triggers
Its ability to reduce debt is crucial for further gains
Near term price trajectory depends on buyback premium, Q2 show
With markets recovering, midcaps have also rebounded and in fact, have outperformed benchmark indices by a good margin in the last two months
Low occupancies, capacity restrictions and safety concerns could make it difficult to reach breakeven levels
Higher chronic sales, US market could offset some of the weakness in sales growth
There could be earnings cuts and lower target prices if the hikes don't materialise this year